TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3999921

Group type: EXPERIMENTAL
Intervention: Debrisoquin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30014331

Group type: EXPERIMENTAL
Intervention: Saline instillation (SI) 20-mL/kg of body weight
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combined strategy of SI and pulmonary recruitment maneuver (RM)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study: 29579496

Group type: EXPERIMENTAL
Intervention: Bathing every four days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bathing every two days
Number of subjects: 32
Study: 26893320

Group type: EXPERIMENTAL
Intervention: Mailings of brochures
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Television advertisements
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Community events
Number of subjects: 174
Study: 25635958

Group type: EXPERIMENTAL
Intervention: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the masseter muscle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the TMJ
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pain in either masseter muscle or TMJ
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pain measured using visual analog scale and McGill Pain Questionnaire
Number of subjects: 16
Study: 23030237

Group type: EXPERIMENTAL
Intervention: Porcine collagen matrix (CM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups (CM and FGG)
Number of subjects: 14
Study: 20559303

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 2203
Study: 18368945

Group type: COMPARATOR
Intervention: Nanopril (test formulation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 26
Study: 17167157

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Toning and stretching control
Number of subjects: 59
Study: 12660531

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 0
Study: 11259720

Group type: EXPERIMENTAL
Intervention: Active pacing (atriobiventricular pacing)
Number of subjects: 48
Study: 9552084

Group type: EXPERIMENTAL
Intervention: Growth hormone injections (n=22)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 50
Study: 7848350

Group type: EXPERIMENTAL
Intervention: Test patch (Deponit 5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference patch
Number of subjects: 0
Study: 3153709

Group type: EXPERIMENTAL
Intervention: oxaprotiline (75, 150, 225 mg/day for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: doxepin (75, 150, 225 mg/day for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: doxepin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: oxaprotiline and doxepin
Number of subjects: 30
Study: 31486370

Group type: EXPERIMENTAL
Intervention: NBTXR3 plus radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 27085700

Group type: EXPERIMENTAL
Intervention: Discography with gadobutrol (group DG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Discoblock with bupivacaine (group DB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (group C)
Number of subjects: 30
Study: 25697965

Group type: EXPERIMENTAL
Intervention: Personalized educational materials
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional interventions only
Number of subjects: 221
Study: 23238616

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (α-LA) 600 mg intravenous injection daily for 5 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Untreated group (saline)
Number of subjects: 63
Study: 21842016

Group type: EXPERIMENTAL
Intervention: Triple-headed toothbrush (DenTrust)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional toothbrush (Bitufo 22)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dentist
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mother
Number of subjects: 20
Study: 18849890

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Atypical antipsychotics (general)
Number of subjects: 130
Study: 17081897

Group type: EXPERIMENTAL
Intervention: 5 IU/mL low-molecular-weight heparin (LMWH) in the infusion fluid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no LMWH)
Number of subjects: 60
Study: 15624745

Group type: EXPERIMENTAL
Intervention: Chemodenervation of sweat glands using botulinum toxin type A (BTX‐A)
Number of subjects: 0
Study: 11699674

Group type: EXPERIMENTAL
Intervention: A trials (children searched for the object after a 10-s delay)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: A trials followed by B trials (children watched as a toy was hidden at Location B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Repeated trials to Location B
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fewer trials to Location A
Number of subjects: 92
Study: 9253337

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DHEA 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7959264

Group type: EXPERIMENTAL
Intervention: Radical vulvectomy with bilateral inguinal lymphadenectomy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Radical hemivulvectomy with selective inguinal lymphadenectomy
Number of subjects: 157

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 157
Study: 30269143

Group type: EXPERIMENTAL
Intervention: Exposure to altitude (2,590 m) after echocardiography at 490 m.
Number of subjects: 37
Study: 30004919

Group type: EXPERIMENTAL
Intervention: Surveillance every 3 months
Number of subjects: 4463

Group type: EXPERIMENTAL
Intervention: Surveillance every 6 months
Number of subjects: 4463

Group type: EXPERIMENTAL
Intervention: Annual surveillance
Number of subjects: 4463

Group type: EXPERIMENTAL
Intervention: More frequent imaging (monthly)
Number of subjects: 4463
Study: 27806902

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 3514

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 3514
Study: 24508204

Group type: EXPERIMENTAL
Intervention: Patients with RAI (n=247)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Patients without RAI (n=63)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Both groups (RAI and non-RAI)
Number of subjects: 310
Study: 22569841

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 353

Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin (Control)
Number of subjects: 353
Study: 19996069

Group type: EXPERIMENTAL
Intervention: Intensive treatment with a systolic blood pressure target of <130 mm Hg, using valsartan (160 or 320 mg) plus amlodipine (5 or 10 mg)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard treatment with a systolic blood pressure target of <140 mm Hg, using valsartan (160 or 320 mg) plus amlodipine (5 or 10 mg)
Number of subjects: 228
Study: 18315978

Group type: EXPERIMENTAL
Intervention: Custom device for measuring dorsal mobility of the first ray of the foot
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified Coleman block test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Klaue device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custom device
Number of subjects: 0
Study: 15987849

Group type: EXPERIMENTAL
Intervention: Calcium phosphate supplementation (CaP; 1.0 g elemental calcium)
Number of subjects: 31
Study: 12721265

Group type: EXPERIMENTAL
Intervention: BMS-247550 at a dose of 6 mg/m2/d administered as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BMS-247550 at a dose of 8 mg/m2/d with filgrastim support
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BMS-247550 at a dose of 6 mg/m2/d
Number of subjects: 27
Study: 10874993

Group type: EXPERIMENTAL
Intervention: Tidal breathing flow-volume loops (TBFVL) in healthy newborns
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tidal breathing flow-volume loops (TBFVL) in infants recovering from respiratory diseases
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tidal breathing flow-volume loops (TBFVL) in infants with bronchopulmonary dysplasia (BPD)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Tidal breathing flow-volume loops (TBFVL) in infants with BPD vs healthy newborns
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tidal breathing flow-volume loops (TBFVL)
Number of subjects: 113
Study: 8604366

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle-strength training program (6 sets of 5 maximal contractions, 3 times per week for 8 weeks on a Cybex II dynamometer at 90 degrees per second)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 2021141

Group type: EXPERIMENTAL
Intervention: 100 micrograms Se/d (as selenium-enriched yeast)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6184769

Group type: EXPERIMENTAL
Intervention: Red krypton laser photocoagulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 68
Study: 30365918

Group type: EXPERIMENTAL
Intervention: DNA barcoding methodologies for identification of parasitoid wasps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wild olives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cultivated olives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eupelmus spermophilus and Utetes africanus
Number of subjects: 0
Study: 30211696

Group type: EXPERIMENTAL
Intervention: 7/10 perceived tightness rating (moderate pressure without pain)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Arterial occlusion pressure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10/10 perceived tightness rating (intense pressure with pain)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between arterial occlusion pressure and 10/10 condition
Number of subjects: 120
Study: 26754752

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 42
Study: 25491299

Group type: EXPERIMENTAL
Intervention: Intravitreal autologous CD34+ BM cell therapy
Number of subjects: 6
Study: 22208833

Group type: EXPERIMENTAL
Intervention: Weekly spaced education e‐mails with content designed to improve teaching skills (group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No e‐mails (group B)
Number of subjects: 29
Study: 20595285

Group type: COMPARATOR
Intervention: Anti-TNF inhibitors (exact type not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model based on differences between baseline and last-visit values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model based on percentage change from baseline
Number of subjects: 0
Study: 17570540

Group type: EXPERIMENTAL
Intervention: Bicycle exercise at 50 W for 30 min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bicycle exercise at 50 W for 60 min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bicycle exercise at 50 W for 120 min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bicycle exercise at 100 W
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7
Study: 16148463

Group type: EXPERIMENTAL
Intervention: Structured abstracts
Number of subjects: 56

Group type: COMPARATOR
Intervention: Unstructured abstracts
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Abstracts published after 1990
Number of subjects: 56
Study: 12401639

Group type: EXPERIMENTAL
Intervention: Wendl tube (28 Ch) kept in position during intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Wendl tube retrieved before intubation)
Number of subjects: 60
Study: 10201758

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (untreated tonsillar fossa)
Number of subjects: 50
Study: 7770402

Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (0.3 ml daily, 3075 anti-Xa IU)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Calcium heparin (0.2 ml-5000 UI if <70 kg or 0.3 ml-7500 IU if ≥70 kg, twice a day)
Number of subjects: 295
Study: 2182705

Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg daily for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (daily for 2 weeks)
Number of subjects: 12
Study: 44234

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other drug treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenoreceptor-blocking drugs (suggested therapy)
Number of subjects: 0
Study: 31470814

Group type: EXPERIMENTAL
Intervention: Non‐channeled King Vision VL
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: McGrath MAC VL
Number of subjects: 99

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 99
Study: 29672935

Group type: EXPERIMENTAL
Intervention: Hawthorn (Crataegus oxyacantha) 160 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27147610

Group type: EXPERIMENTAL
Intervention: IC adenosine (2-3 mg total)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (500 μg total)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control (standard PPCI)
Number of subjects: 247
Study: 24599772

Group type: EXPERIMENTAL
Intervention: Exercise programme with leucine supplementation (10 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study: 22465904

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d) plus zinc (440 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 23
Study: 19293160

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study: 18035427

Group type: EXPERIMENTAL
Intervention: CIPRODEX Otic Suspension (CIP/DEX) - four drops instilled into each middle ear through tympanostomy tubes
Number of subjects: 25
Study: 16101608

Group type: EXPERIMENTAL
Intervention: 600 microg oral misoprostol
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Standard treatment with four 0.5-mg ergometrine tablets
Number of subjects: 1229
Study: 12808615

Group type: EXPERIMENTAL
Intervention: Octreotide in combination with IFN-alpha
Number of subjects: 68

Group type: COMPARATOR
Intervention: Octreotide alone
Number of subjects: 68
Study: 10996770

Group type: EXPERIMENTAL
Intervention: Color-coded duplex ultrasound
Number of subjects: 46

Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 46
Study: 8796157

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no acetazolamide)
Number of subjects: 23
Study: 1602956

Group type: EXPERIMENTAL
Intervention: Mannitol (250 cc intravenous at 20% injected in 1 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (intravenous perfusion glucose serum 250 cc with 1 g of vitamins C, 250 mg of vitamin B6 and 1 g of calcium gluconate injected in 1 h)
Number of subjects: 0
Study: 3902523

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG) administered intramuscularly, initial dosage of 10,000 IU followed by 5,000 IU twice weekly up to week 12, then once weekly up to week 16
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31408237

Group type: EXPERIMENTAL
Intervention: NicAlert reading of 1
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: NicAlert reading of 2
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: NicAlert reading of 3
Number of subjects: 92
Study: 28581284

Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 1.5%
Number of subjects: 295

Group type: COMPARATOR
Intervention: Topical mydriatic
Number of subjects: 295
Study: 26642868

Group type: EXPERIMENTAL
Intervention: Within-list retrieval practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extra-list retrieval practice
Number of subjects: 0
Study: 24809882

Group type: EXPERIMENTAL
Intervention: Clocortolone pivalate cream 0.1% (Cloderm Cream, Promius Pharma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate lipocream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated damaged control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated normal skin
Number of subjects: 0
Study: 22869562

Group type: EXPERIMENTAL
Intervention: GS-9451 60 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS-9451 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS-9451 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS-9451 200 mg and 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NS3 clinical mutants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS-9451
Number of subjects: 0
Study: 19383902

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol intervention
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol intervention (highest quintile at baseline)
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol intervention (3-year follow-up measurement)
Number of subjects: 1891

Group type: COMPARATOR
Intervention: Beta-carotene, serum retinol, and supplemental beta-carotene
Number of subjects: 1891
Study: 17479308

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 34
Study: 15668859

Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin (1000 mg single dose followed by 500 mg one week later)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous vancomycin (administered twice daily for 14 days)
Number of subjects: 75
Study: 11886001

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel 35 mg/m2, gemcitabine 800 mg/m2 and cisplatin 35 mg/m2, on days 1 and 8 every 3 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel, gemcitabine and cisplatin
Number of subjects: 35
Study: 9704782

Group type: EXPERIMENTAL
Intervention: Abnormal glucose tolerance
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal glucose tolerance
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Changes in fat mass
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Changes in basal VO2
Number of subjects: 16
Study: 7641363

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan-Captopril combination
Number of subjects: 12
Study: 2238185

Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg once daily
Number of subjects: 266

Group type: COMPARATOR
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide 12.5 mg daily (as a supplement to spirapril)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Hydrochlorthiazide (as a supplement to nitrendipine)
Number of subjects: 266
Study: 356658

Group type: EXPERIMENTAL
Intervention: Metoprolol 1%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoprolol 2%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoprolol 4%
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoprolol (all concentrations)
Number of subjects: 13
Study: 31215156

Group type: EXPERIMENTAL
Intervention: 0.25% Timosaponin A-III (TA-III)
Number of subjects: 21
Study: 31580781

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Versawave, Hoya ConBio, San Francisco, CA; 40 hz, 50 mJ/pulse)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Scalpel (control site)
Number of subjects: 5
Study: 27925437

Group type: EXPERIMENTAL
Intervention: 6-month WLM program (WL + WLM; n = 47)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No resources (WL-only; n = 45)
Number of subjects: 92
Study: 26277033

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24686345

Group type: EXPERIMENTAL
Intervention: Fast-track (FT) rehabilitation program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care (SC) program
Number of subjects: 52
Study: 22444187

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naloxone pretreatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous saline pretreatment
Number of subjects: 24
Study: 19240066

Group type: EXPERIMENTAL
Intervention: Dual-DES
Number of subjects: 1007

Group type: COMPARATOR
Intervention: SES
Number of subjects: 1007

Group type: COMPARATOR
Intervention: ZES
Number of subjects: 1007
Study: 17827503

Group type: EXPERIMENTAL
Intervention: rescue angioplasty (rPCI) in MERLIN trial
Number of subjects: 0
Study: 15450054

Group type: EXPERIMENTAL
Intervention: Withdrawal of antipsychotic medications
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continued treatment with antipsychotic medications
Number of subjects: 30
Study: 11588698

Group type: EXPERIMENTAL
Intervention: Caspofungin 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B 0.5 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0